title: Rapid and frequent induction of protective immunity exceeding UK recommendations for healthcare settings by MF59-adjuvated hepatitis B vaccine.
abstract: The ability of three doses of a novel MF59-adjuvanted hepatitis B virus (HBV) vaccine containing surface and pre-S2 antigens given at 0, 1, and 6 months to induce levels of HBV surface antibody (sAb) > or = 100 mIU/ml was compared with a UK licensed alum-adjuvanted yeast-derived HBV vaccine in HBV-naive healthcare workers (HCWs). One month after second immunization with HBV/MF59, 100% of HCWs had sAb > or = 100 mIU/mL, compared with only 11% and 85% after two or three immunisations with Engerix-B. The sAb GMT of the Engerix B immunised group remained below 100 mIU/mL until month seven, (compared with month one for HBV/MF59), and was 123-fold lower at this time (208,561 vs. 1,686 mIU/mL). In our subjects HBV/MF59 vaccine rapidly induced sAb to levels far in excess of those recommended by the Department of Health for high-risk situations (e.g. HCWs and patients on dialysis). It has the potential for shorter schedules and reduced need for serology and boosters.
authors.affiliation: St George's Vaccine Institute, St George's Hospital Medical School, London. d.lewis@sghms.ac.uk
authors.forename: D J
authors.initials: DJ
authors.lastname: Lewis
authors.forename: J E
authors.initials: JE
authors.lastname: Eiden
authors.forename: C
authors.initials: C
authors.lastname: Goilav
authors.forename: A G
authors.initials: AG
authors.lastname: Langenberg
authors.forename: F
authors.initials: F
authors.lastname: Suggett
authors.forename: G E
authors.initials: GE
authors.lastname: Griffin
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000293:Adolescent; D000328:Adult; D005260:Female; D006510:Hepatitis B Antibodies / Q000096:biosynthesis / Q000097:blood; D017325:Hepatitis B Vaccines / Q000008:administration & dosage / Q000276:immunology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011136:Polysorbates / Q000008:administration & dosage*; D017410:Practice Guidelines as Topic; D013185:Squalene / Q000008:administration & dosage*; D006113:United Kingdom
chemical_list: D000276:Adjuvants, Immunologic; D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines; C089950:MF59 oil emulsion; D011136:Polysorbates; D013185:Squalene